Bristol Myers Squibb stock holds firm as autoimmune CAR-T trials are paused
Published on 09/01/2026 at 16:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) is trading steadily in the mid-60 USD range, with recent data showing a closing price of 66.47 USD on the NYSE as of August 30, 2026, and an intraday band between 66.19 and 67.39 USD, keeping the shares in a tight consolidation zone ahead of further trial updates.
Autoimmune CAR-T trial pause shapes sentiment
According to a MedPath summary of clinical developments published on September 1, 2026, Bristol Myers Squibb has voluntarily paused enrollment in autoimmune trials evaluating its CAR-T treatment zolacabtagene autoleucel, also known as zola-cel, after the detection of transient and reversible inflammatory events during routine safety monitoring.
The company signaled that the pause is being implemented out of caution while clinical and safety data across the zola-cel program are reviewed, with the stated aim of completing the assessment and resuming testing as quickly as possible once regulators and investigators are aligned on any protocol changes.
Stock reaction and valuation context
Recent quote snapshots compiled by Yahoo Finance for the BMY ticker indicate that Bristol Myers Squibb shares have remained close to 66 USD in late August 2026, with the August 30, 2026 closing price of 66.47 USD leaving the stock broadly unchanged over the past few sessions despite the autoimmune CAR-T headlines.
This price level keeps Bristol Myers Squibb in a valuation range where many large-cap biopharmaceutical peers trade on mid-teens earnings multiples, and while the pause introduces uncertainty for the autoimmune indication roadmap, the core oncology and immunology franchises continue to underpin revenue and cash flow that support the current market capitalization level reported around the mid tens of billions of USD as of late August 2026.
Further details on Bristol Myers Squibb stock and filings
Investors can find more regulatory filings, corporate news and historic price developments for Bristol Myers Squibb via the issuer overview and the company's own investor relations materials.
Key products and late-stage pipeline
Bristol Myers Squibb generates a substantial part of its revenue from established oncology and immunology products such as the checkpoint inhibitor nivolumab and the multiple myeloma therapies in its portfolio, while newer cell therapies and autoimmune-focused candidates like zola-cel are intended to broaden the company's reach beyond current indications over the coming years.
Stock price and investor perspective
As of August 30, 2026, Bristol Myers Squibb stock closed at 66.47 USD on the NYSE, leaving the shares near the middle of their recent trading band and giving investors time to weigh the impact of the autoimmune CAR-T trial pause against the company's broader earnings power and product mix.
Bristol Myers Squibb at a glance
- Company: Bristol Myers Squibb Company Inc.
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: NYSE
- Price (as of August 30, 2026, 15:59): 66.47 USD
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
